John Treace - Treace Medical Founder CEO
| TMCI Stock | USD 5.75 0.16 2.71% |
Insider
John Treace is Founder CEO of Treace Medical Concepts
| Age | 52 |
| Address | 100 Palmetto Park Place, Ponte Vedra, FL, United States, 32081 |
| Phone | 904 373 5940 |
| Web | https://www.treace.com |
John Treace Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Treace against Treace Medical stock is an integral part of due diligence when investing in Treace Medical. John Treace insider activity provides valuable insight into whether Treace Medical is net buyers or sellers over its current business cycle. Note, Treace Medical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Treace Medical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Treace over three months ago Acquisition by John Treace of 178325 shares of Treace Medical subject to Rule 16b-3 | ||
John Treace over a year ago Sale by John Treace of 2075 shares of Treace Medical |
Treace Medical Management Efficiency
The company has return on total asset (ROA) of (0.1433) % which means that it has lost $0.1433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3856) %, meaning that it created substantial loss on money invested by shareholders. Treace Medical's management efficiency ratios could be used to measure how well Treace Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.23. The current Return On Capital Employed is estimated to decrease to -0.26. As of now, Treace Medical's Asset Turnover is decreasing as compared to previous years.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mary Moreland | Abbott Laboratories | 58 | |
| Andrea Wainer | Abbott Laboratories | 55 | |
| Gregory Ahlberg | Abbott Laboratories | 54 | |
| Lisa Earnhardt | Abbott Laboratories | 54 | |
| Alejandro Wellisch | Abbott Laboratories | 49 | |
| Christopher Calamari | Abbott Laboratories | 50 | |
| Christopher Scoggins | Abbott Laboratories | 54 | |
| Michael Dale | Abbott Laboratories | 61 | |
| Michael Roman | Abbott Laboratories | 61 | |
| John Ginascol | Abbott Laboratories | 62 | |
| James Young | Abbott Laboratories | N/A | |
| Louis Morrone | Abbott Laboratories | 44 | |
| Philip Boudreau | Abbott Laboratories | 51 | |
| Sammy Karam | Abbott Laboratories | 59 | |
| Cary Majors | STERIS plc | 49 | |
| J Zangerle | STERIS plc | 53 | |
| Randel Woodgrift | Abbott Laboratories | 59 | |
| John Zangerle | STERIS plc | 57 | |
| Michael Pederson | Abbott Laboratories | 59 | |
| Elaine Leavenworth | Abbott Laboratories | 65 | |
| Charles Brynelsen | Abbott Laboratories | 63 | |
Management Performance
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.14 |
Treace Medical Concepts Leadership Team
Elected by the shareholders, the Treace Medical's board of directors comprises two types of representatives: Treace Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Treace. The board's role is to monitor Treace Medical's management team and ensure that shareholders' interests are well served. Treace Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Treace Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shana Zink, Medical Affairs | ||
| Julie Dewey, Chief Officer | ||
| Scot JD, Chief Secretary | ||
| Thomas Timbie, Independent Director | ||
| John Treace, Founder CEO | ||
| Sean Scanlan, Chief Officer | ||
| Nathan Minnich, Senior Marketing | ||
| Scot Elder, Chief Secretary | ||
| Mark CPA, Chief Officer | ||
| Aaron Berutti, Senior Sales | ||
| Jaime Frias, Chief Officer | ||
| Daniel Owens, Chief Officer | ||
| Terry Lubben, Senior Operations |
Treace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Treace Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 326.46 M | ||||
| Shares Outstanding | 62.01 M | ||||
| Shares Owned By Insiders | 27.82 % | ||||
| Shares Owned By Institutions | 68.46 % | ||||
| Number Of Shares Shorted | 4.55 M | ||||
| Price To Book | 5.33 X |
Currently Active Assets on Macroaxis
| CART | Maplebear Common Stock | |
| OPK | Opko Health | |
| AVAI | Avant Technologies | |
| VEOEY | Veolia Environnement SA | |
| GOOG | Alphabet Inc Class C |
Additional Information and Resources on Investing in Treace Stock
When determining whether Treace Medical Concepts offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Treace Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Treace Medical Concepts Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Treace Medical Concepts Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Treace Medical Concepts. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Treace Medical. If investors know Treace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Treace Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Revenue Per Share 3.181 | Quarterly Revenue Growth 0.211 | Return On Assets (0.14) | Return On Equity (0.39) |
The market value of Treace Medical Concepts is measured differently than its book value, which is the value of Treace that is recorded on the company's balance sheet. Investors also form their own opinion of Treace Medical's value that differs from its market value or its book value, called intrinsic value, which is Treace Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Treace Medical's market value can be influenced by many factors that don't directly affect Treace Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Treace Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Treace Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Treace Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.